<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="55342"><DrugName>hydroxyprogesterone caproate (long-acting, preterm birth prevention), Adeza</DrugName><DrugNamesKey><Name id="43000361">Gestiva</Name><Name id="43000358">Makena</Name><Name id="43089827">Makena SQ</Name><Name id="43012732">hydroxyprogesterone caproate</Name></DrugNamesKey><DrugSynonyms><Name><Value>17alpha-hydroxyprogesterone caproate</Value></Name><Name><Value>naturally-occuring progesterone (long-acting, preterm birth prevention), Adeza</Value></Name><Name><Value>17alpha-hydroxyprogesterone hexanoate</Value></Name><Name><Value>Makena</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Gestiva</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>17alpha-hydroxyprogesterone caproate (long-acting, preterm birth prevention), Adeza</Value></Name><Name><Value>hydroxyprogesterone caproate</Value><Types><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>hydroxyprogesterone caproate (long-acting, preterm birth prevention), Adeza</Value></Name><Name><Value>Makena SQ</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>630-56-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="13722">Adeza Biomedical Corp</CompanyOriginator><CompaniesPrimary><Company id="13726">AMAG Pharmaceuticals Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1008688">Hologic Inc</Company><Company id="13722">Adeza Biomedical Corp</Company><Company id="17712">Lumara Health Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="55342" type="Drug"><TargetEntity id="420234" type="siDrug">17-Hydroxyprogesterone caproate</TargetEntity></SourceEntity><SourceEntity id="1008688" type="Company"><TargetEntity id="4295906709" type="organizationId">Hologic Inc</TargetEntity></SourceEntity><SourceEntity id="13722" type="Company"><TargetEntity id="5001348014" type="organizationId">Adeza Biomedical Corp</TargetEntity></SourceEntity><SourceEntity id="13726" type="Company"><TargetEntity id="4295903284" type="organizationId">AMAG Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="17712" type="Company"><TargetEntity id="5000184431" type="organizationId">KV Pharmaceutical Company Ltd</TargetEntity></SourceEntity><SourceEntity id="455" type="ciIndication"><TargetEntity id="O60" type="ICD10"></TargetEntity><TargetEntity id="10036600" type="MEDDRA"></TargetEntity><TargetEntity id="D007752" type="MeSH"></TargetEntity><TargetEntity id="-699701292" type="omicsDisease"></TargetEntity><TargetEntity id="567" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="624" type="Action"><TargetEntity id="559" type="Mechanism">Progesterone Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-01604" type="ciTarget"><TargetEntity id="14903792952413" type="siTarget">Progesterone receptor</TargetEntity><TargetEntity id="1100" type="omicsTarget"></TargetEntity><TargetEntity id="-1973148911" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Premature labor - US - Mar-2011</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="455">Premature labor</Indication></IndicationsPrimary><ActionsPrimary><Action id="624">Progesterone receptor agonist</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="589">Sustained release formulation</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="746">Solution</Technology></Technologies><EphmraCodes><Ephmra><Code>G3D</Code><Name>PROGESTOGENS, EXCLUDING G3A, G3F</Name></Ephmra></EphmraCodes><LastModificationDate>2019-04-15T05:47:19.000Z</LastModificationDate><ChangeDateLast>2019-04-15T00:00:00.000Z</ChangeDateLast><AddedDate>2006-05-08T17:15:03.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="13722" linkType="Company"&gt;Adeza&lt;/ulink&gt;, a wholly-owned subsidiary of &lt;ulink linkID="1008688" linkType="Company"&gt;Hologic&lt;/ulink&gt;, has developed, and  licensee &lt;ulink linkID="13726" linkType="Company"&gt;AMAG Pharmaceuticals&lt;/ulink&gt; (following its acquisition of &lt;ulink linkID="17712" linkType="Company"&gt;Lumara Health&lt;/ulink&gt;; formerly KV Pharmaceutical) has launched Makena (formerly Gestiva; Makena SQ), a long-acting injectable form of the naturally-occurring progesterone hydroxyprogesterone caproate. The product is indicated in the US to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth [&lt;ulink linkID="1638538" linkType="Reference"&gt;1638538&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, the drug was launched in the US [&lt;ulink linkID="1174252" linkType="Reference"&gt;1174252&lt;/ulink&gt;]; however, in March 2019, negative topline data were reported from the  PROLONG trial that had been  conducted as part of the approval commitment under the FDA accelerated approval process;  additional sub-group analyses were planned [&lt;ulink linkID="2127608" linkType="Reference"&gt;2127608&lt;/ulink&gt;]. In April 2016, a single-dose, preservative-free formulation of Makena was launched in the US [&lt;ulink linkID="1748634" linkType="Reference"&gt;1748634&lt;/ulink&gt;].  In February 2018, the FDA approved an sNDA for the Makena sc QuickShot auto injector device [&lt;ulink linkID="2005350" linkType="Reference"&gt;2005350&lt;/ulink&gt;]; by November 2018, the autoinjector product had been launched [&lt;ulink linkID="2091318" linkType="Reference"&gt;2091318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, although a global phase III trial was ongoing because of the small patient pool of the drug in order to comply with post-approval commitments AMAG stated that it was not planning to commercialize the drug outside of the US [&lt;ulink linkID="1638724" linkType="Reference"&gt;1638724&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In March 2007, Adeza stated that it held no patent protection for Makena and was thus reliant on Orphan Drug exclusivity, which expired in FebruaryÂ 3, 2018 [&lt;ulink linkID="1638724" linkType="Reference"&gt;1638724&lt;/ulink&gt;],  [&lt;ulink linkID="1638602" linkType="Reference"&gt;1638602&lt;/ulink&gt;]. In October 2007,  Orphan Drug designation  was challenged by a petition filed by a third party    [&lt;ulink linkID="1638639" linkType="Reference"&gt;1638639&lt;/ulink&gt;]. In February 2011, the FDA stated that it would not take enforcement action against compounding pharmacies producing compounded 17-alpha hydroxyprogesterone caproate in response to individual prescriptions for individual patients to ensure continued access to the drug [&lt;ulink linkID="1180485" linkType="Reference"&gt;1180485&lt;/ulink&gt;], [&lt;ulink linkID="1638664" linkType="Reference"&gt;1638664&lt;/ulink&gt;]. In June 2012, the FDA stated that approved drug products, such as Makena, provided greater safety and effectiveness than the compounded equivalent products [&lt;ulink linkID="1638724" linkType="Reference"&gt;1638724&lt;/ulink&gt;], [&lt;ulink linkID="1301712" linkType="Reference"&gt;1301712&lt;/ulink&gt;]. In July 2012, KV sued the FDA stating that the agency was not addressing the need of patients and was instead considering the financial concerns of insurance companies  [&lt;ulink linkID="1639839" linkType="Reference"&gt;1639839&lt;/ulink&gt;]. In September 2012, the case was dismissed [&lt;ulink linkID="1639850" linkType="Reference"&gt;1639850&lt;/ulink&gt;]. In July 2014, the FDA reaffirmed the position it took in its June 2012 press release recommending the use of approved drug products over compounded, except where there is specific need [&lt;ulink linkID="1638724" linkType="Reference"&gt;1638724&lt;/ulink&gt;]. In February 2016, AMAG reported  it had filed provisional IP on the sc autoinjector formulation and that &lt;ulink linkID="28494" linkType="Company"&gt;Antares Pharma&lt;/ulink&gt; held multiple issued patents that cover the autoinjector [&lt;ulink linkID="1736130" linkType="Reference"&gt;1736130&lt;/ulink&gt;]. In April 2017, AMAG reported that if the Makena autoinjector was approved, it would request Orange Book listing of the eligible Antares patents, the last of which expires in 2026 [&lt;ulink linkID="1918165" linkType="Reference"&gt;1918165&lt;/ulink&gt;]. In December 2017, a US patent related to the Makena autoinjector was issued (set to expire in 2036); in March 2018, a  patent application related to the Makena autoinjector  product was pending [&lt;ulink linkID="2010222" linkType="Reference"&gt;2010222&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2019, Sun Pharmaceutical received FDA approval of its generic hydroxyprogesterone caproate injection (1250 mg/5 ml) [&lt;ulink linkID="2141196" linkType="Reference"&gt;2141196&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2019, &lt;ulink linkID="1168097" linkType="Company"&gt;Slayback Pharma&lt;/ulink&gt; received FDA approval of its generic hydroxyprogesterone caproate injection (1250 mg/5 ml) in a multi-dose vial [&lt;ulink linkID="2107549" linkType="Reference"&gt;2107549&lt;/ulink&gt;]. Later that month, the generic was launched [&lt;ulink linkID="2112446" linkType="Reference"&gt;2112446&lt;/ulink&gt;]. In March 2019, final US FDA approval was granted for Slayback's generic version of the drug in a single dose vial (250 mg/ 1 ml)  [&lt;ulink linkID="2133224" linkType="Reference"&gt;2133224&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2018, a generic version from &lt;ulink linkID="24732" linkType="Company"&gt;Luitpold Pharmaceuticals&lt;/ulink&gt; (a subsidiary of Daiichi Sankyo) (250 mg/ml injection) was approved by the FDA [&lt;ulink linkID="2058014" linkType="Reference"&gt;2058014&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2018, &lt;ulink linkID="DOL1000004" linkType="Company"&gt;American Regent&lt;/ulink&gt;'s generic version of hydroxyprogesterone caproate (250 mg/ml injection) was approved and launched [&lt;ulink linkID="2049914" linkType="Reference"&gt;2049914&lt;/ulink&gt;]. In August 2018, American Regent partnered with &lt;ulink linkID="1027030" linkType="Company"&gt;Amneal Pharmaceuticals&lt;/ulink&gt; for the distribution of the generic to retail consortiums; American Regent retained the  marketing of the product in all other channels [&lt;ulink linkID="2068091" linkType="Reference"&gt;2068091&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, AMAG planned  to launch an authorized generic version of the im formulation of Makena with an undisclosed  generic partner on the first entry of generic competition into the market  [&lt;ulink linkID="2010222" linkType="Reference"&gt;2010222&lt;/ulink&gt;]. In February 2018, AMAG partnered with &lt;ulink linkID="1049169" linkType="Company"&gt;Prasco&lt;/ulink&gt; for the authorized generic; the authorized generic was launched in July 2018 [&lt;ulink linkID="2095765" linkType="Reference"&gt;2095765&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In  January 2018,  loss of Makena orphan drug exclusivity was expected by February 03, 2018  [&lt;ulink linkID="1995994" linkType="Reference"&gt;1995994&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2016, AMAG planned to file an sNDA in the US for a sc formulation/auto injector device [&lt;ulink linkID="1738243" linkType="Reference"&gt;1738243&lt;/ulink&gt;]. In April 2017, AMAG submitted an sNDA to the US FDA for a Makena sc auto-injector [&lt;ulink linkID="1918165" linkType="Reference"&gt;1918165&lt;/ulink&gt;]; in June 2017, the FDA accepted the filing for review with a PDUFA date of February 14, 2018  [&lt;ulink linkID="1941154" linkType="Reference"&gt;1941154&lt;/ulink&gt;]; in February 2018, the FDA approved the sNDA for the Makena sc QuickShot auto injector device [&lt;ulink linkID="2005350" linkType="Reference"&gt;2005350&lt;/ulink&gt;]. In March 2018, the auto injector was expected to launch that month [&lt;ulink linkID="2010222" linkType="Reference"&gt;2010222&lt;/ulink&gt;];  by November 2018, the product had been launched [&lt;ulink linkID="2091318" linkType="Reference"&gt;2091318&lt;/ulink&gt;]. In January 2019, AMAG reported that supply issues had been experienced in 4Q18 [&lt;ulink linkID="2108850" linkType="Reference"&gt;2108850&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, AMAG reported that the company was developing a device for the sc administration of Makena by an auto-injector [&lt;ulink linkID="1709301" linkType="Reference"&gt;1709301&lt;/ulink&gt;]. In January 2016, the company disclosed that it was partnering with Antares Pharma on the sc auto-injector program. In February 2016, AMAG planned to complete a pharmacokinetic bioequivalence study in healthy volunteers. At that time, a superiority study versus the im formulation was also planned, which if positive would provide 7 years of orphan drug exclusivity for the sc formulation/device combination, and discussions with the FDA were continuing regarding the best path forward [&lt;ulink linkID="1736130" linkType="Reference"&gt;1736130&lt;/ulink&gt;]. In October 2016,  both trials for the sc auto-injector, as Makena SQ, were initiated [&lt;ulink linkID="1806578" linkType="Reference"&gt;1806578&lt;/ulink&gt;].  In February 2017, positive data from the pharmacokinetic bioequivalence study were reported [&lt;ulink linkID="1897647" linkType="Reference"&gt;1897647&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2014, AMAG filed with the FDA a prior approval sNDA for a preservative-free, single-dose 1-ml vial of the drug as a part of multi-pronged line extension/lifecycle management program. At that time, decision from the  FDA was expected in 2Q15 [&lt;ulink linkID="1625688" linkType="Reference"&gt;1625688&lt;/ulink&gt;], [&lt;ulink linkID="1638724" linkType="Reference"&gt;1638724&lt;/ulink&gt;]. In January 2015, AMAG met with the FDA seeking regulatory advice on the line extension [&lt;ulink linkID="1639972" linkType="Reference"&gt;1639972&lt;/ulink&gt;]. In May 2015, the FDA issued a Complete Response letter, requesting additional information related to manufacturing procedures for the single-dose vial at a new third-party manufacturer. At that time, AMAG expected to launch the product in 4Q15 [&lt;ulink linkID="1664249" linkType="Reference"&gt;1664249&lt;/ulink&gt;]. In November 2015, the FDA issued a further Complete Response letter requesting additional information regarding the single-dose vial of hydroxyprogesterone caproate sNDA [&lt;ulink linkID="1714649" linkType="Reference"&gt;1714649&lt;/ulink&gt;].  Later in November 2015, AMAG responded to the Complete Response letter providing the additional information and data requested [&lt;ulink linkID="1715531" linkType="Reference"&gt;1715531&lt;/ulink&gt;]. In February 2016, the single-dose, preservative-free formulation of Makena was approved in the US [&lt;ulink linkID="1737244" linkType="Reference"&gt;1737244&lt;/ulink&gt;]; in April 2016, the single-dose, preservative-free version of Makena was launched [&lt;ulink linkID="1748634" linkType="Reference"&gt;1748634&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt; In October 2006, the FDA issued  an approvable letter requesting an additional preclinical study and  postmarketing clinical data. At that time,  the company was also discussing its Orphan Drug application with the agency. Adeza's initial request for Orphan status had not been  granted and the company was to provide additional new data for further review  [&lt;ulink linkID="733863" linkType="Reference"&gt;733863&lt;/ulink&gt;]. In January 2007, Makena was granted Orphan Drug status by the FDA for premature labor [&lt;ulink linkID="762198" linkType="Reference"&gt;762198&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2006, Adeza  submitted an NDA for the agent  under the FDA's section 505(b)(2) procedure [&lt;ulink linkID="665818" linkType="Reference"&gt;665818&lt;/ulink&gt;]. In June 2006, it was granted  Priority Review, with a PDUFA data of October 20, 2006 [&lt;ulink linkID="671535" linkType="Reference"&gt;671535&lt;/ulink&gt;]. In July 2006, the FDA accepted  the NDA for filing  [&lt;ulink linkID="677317" linkType="Reference"&gt;677317&lt;/ulink&gt;], [&lt;ulink linkID="678868" linkType="Reference"&gt;678868&lt;/ulink&gt;]. In August 2006, the FDA's Reproductive Health Drugs Advisory Committee recommended approval of the drug. The Committee also recommended the company collect post-marketing clinical data [&lt;ulink linkID="686673" linkType="Reference"&gt;686673&lt;/ulink&gt;]. By August 2008, a PDUFA date had been set for October 24, 2008 [&lt;ulink linkID="933739" linkType="Reference"&gt;933739&lt;/ulink&gt;]. In October 2008, the FDA extended the PDUFA date from October 24, 2008 to January 25, 2009 [&lt;ulink linkID="953988" linkType="Reference"&gt;953988&lt;/ulink&gt;]. In January 2009, the FDA issued a complete response letter and stated the post-approval trial of the drug should enroll a portion of its subjects before the drug could be approved [&lt;ulink linkID="979167" linkType="Reference"&gt;979167&lt;/ulink&gt;]. By May 2010, enrollment in the trial was underway [&lt;ulink linkID="1095599" linkType="Reference"&gt;1095599&lt;/ulink&gt;]. In July 2010, Hologic made a resubmission to the complete response letter [&lt;ulink linkID="1115910" linkType="Reference"&gt;1115910&lt;/ulink&gt;]. By November 2010, the drug had an action date of January 13, 2011 [&lt;ulink linkID="1148725" linkType="Reference"&gt;1148725&lt;/ulink&gt;]. In January 2011, Hologic submitted  additional information requested by FDA; at that time the PDUFA  date was extended to April 13, 2011 [&lt;ulink linkID="1160702" linkType="Reference"&gt;1160702&lt;/ulink&gt;].  In February 2011, the FDA approved Makena [&lt;ulink linkID="1165824" linkType="Reference"&gt;1165824&lt;/ulink&gt;], [&lt;ulink linkID="1165829" linkType="Reference"&gt;1165829&lt;/ulink&gt;], [&lt;ulink linkID="1165828" linkType="Reference"&gt;1165828&lt;/ulink&gt;]. In March 2011, the drug was launched  [&lt;ulink linkID="1174252" linkType="Reference"&gt;1174252&lt;/ulink&gt;]. In February 2015, AMAG stated that  it was conducting global clinical studies as part of the FDA's "SubpartÂ H" accelerated approval regulation, including a safety and efficacy   clinical study, a  follow-up study of the babies born to mothers from the safety and efficacy clinical study, andÂ a completed pharmacokinetic study [&lt;ulink linkID="1638724" linkType="Reference"&gt;1638724&lt;/ulink&gt;]; in October 2015, AMAG requested an extension for the agreed completion dates for two of the remaining studies;  the FDA subsequently approved a two-year extension to December 2018 and October 2020 for the  safety and efficacy   clinical study and  the follow-up study, respectively  [&lt;ulink linkID="1738243" linkType="Reference"&gt;1738243&lt;/ulink&gt;]; however, in March 2019, negative topline data were reported for the PROLONG trial;  additional sub-group analyses were planned [&lt;ulink linkID="2127608" linkType="Reference"&gt;2127608&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In March 2017, data were published from a US study in pregnant women carrying a single fetus and with a prior history of premature births. A total of 430 women were treated with compounded hydroxyprogesterone caproate between 2012 and 2016. Of the women treated, 25% had recurrent preterm birth compared with a 16.8% historical premature birth rate from 5,787 women who also had prior preterm births but did not receive the drug [&lt;ulink linkID="1908757" linkType="Reference"&gt;1908757&lt;/ulink&gt;], [&lt;ulink linkID="1908599" linkType="Reference"&gt;1908599&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2010, a prospective, noninterventional, follow-upÂ study (&lt;ulink linkID="67604" linkType="Protocol"&gt;NCT01146990&lt;/ulink&gt;;Â 17P-FU-004) was intiated in the US and Europe to evaluate the differences in developmental outcomes of children, aged 23 to 25 months, born to mothers who participated in the 17P efficacy trial, &lt;ulink linkID="61507" linkType="Protocol"&gt;NCT01004029&lt;/ulink&gt;  [&lt;ulink linkID="2048786" linkType="Reference"&gt;2048786&lt;/ulink&gt;]. By February 2016,   the FDA had approved a two-year extension to October 2020 for the  completion of the study; at that time the trial was ongoing [&lt;ulink linkID="1738243" linkType="Reference"&gt;1738243&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2009, a randomized, double-blind, placebo-controlled, phase IIIb trial (&lt;ulink linkID="61507" linkType="Protocol"&gt;NCT01004029&lt;/ulink&gt;, 17P-ES-003; PROLONG) began in pregnant women with a history of preterm birth (expected n = 1707) in the US, Europe and Canada. The  study  included a population pharmacokinetic substudy.Â At that time, the expected completion date was June 2014  [&lt;ulink linkID="1095795" linkType="Reference"&gt;1095795&lt;/ulink&gt;], [&lt;ulink linkID="1095599" linkType="Reference"&gt;1095599&lt;/ulink&gt;], [&lt;ulink linkID="1095795" linkType="Reference"&gt;1095795&lt;/ulink&gt;]. By February 2015, the global pharmacokinetic study of mothers receiving the drug had completed. At that time, AMAG commented on the  trial stating that although it had no commercialization plans outside the US, the global trial was conducted because of the small patient pool for the drug  and in order to comply with post-approval commitments [&lt;ulink linkID="1638724" linkType="Reference"&gt;1638724&lt;/ulink&gt;]. By February 2016,   the FDA had approved a two-year extension and the trial was expected to complete in December 2018 [&lt;ulink linkID="1738243" linkType="Reference"&gt;1738243&lt;/ulink&gt;].  In March 2019, topline data were reported which showed no difference between the treatment and placebo arms for the co-primary endpoints; the incidence of preterm delivery at less than 35 weeks (Makena treated group 11.0% versus placebo 11.5%, p = 0.72) and the percentage of patients who met criteria for the pre-specified neonatal morbidity and mortality composite index (Makena treated group 5.4% versus 5.2%,  p = 0.84). At that time, additional sub-group analyses were planned [&lt;ulink linkID="2127608" linkType="Reference"&gt;2127608&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In February 2016, AMAG reported that pilot studies of the sc formulation/auto-injector combination were being completed. At that time, the company planned to complete a pharmacokinetic bioequivalence study of the sc formulation/auto injector combination  in healthy volunteers   [&lt;ulink linkID="1736130" linkType="Reference"&gt;1736130&lt;/ulink&gt;]. In October 2016, the first patient was dosed in the multicenter, randomized, open-label, phase I study (&lt;ulink linkID="276571" linkType="Protocol"&gt;NCT02940522&lt;/ulink&gt;; AMAG-HPC-PK-010) in US to assess the bioavailability of Makena (intramuscular or sc injection) in healthy post-menopausal women (expected n = 120). The primary endpoint was comparison of Cmax and AUC [&lt;ulink linkID="1867251" linkType="Reference"&gt;1867251&lt;/ulink&gt;], [&lt;ulink linkID="1806578" linkType="Reference"&gt;1806578&lt;/ulink&gt;]. In February 2017, data were reported showing that the trial met the bioequivalence endpoint as measured by AUC but not as measured by Cmax. The 90% confidence interval for AUC ratio was 105.17 to 124.39, which fell within the 80 to 125% range used by the FDA to define bioequivalence. The 90% confidence interval for Cmax ratio was 96.6 to 138.7%, which fell outside the  80 to 125% bioequivalence range [&lt;ulink linkID="1897647" linkType="Reference"&gt;1897647&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2016, AMAG also  planned to complete a superiority study versus the im formulation  [&lt;ulink linkID="1736130" linkType="Reference"&gt;1736130&lt;/ulink&gt;]. In October 2016,  the comparative, 1:1-randomized, open-label, parallel-group-assignment study to compare the average injection pain of four weekly injections between the sc and im injections of Makena using a validated pain scale in healthy post-menopausal women (expected n = 60) was initiated with the first patient dosed [&lt;ulink linkID="1806578" linkType="Reference"&gt;1806578&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By May 2006, an NIH-conducted study of Makena had been completed.  The multicenter, double-blind, placebo-controlled trial involved 463 women with a history of preterm birth, who were enrolled between 16 and 21 weeks of gestation. The women were administered weekly injections of the drug or placebo until delivery or 37 weeks gestation. A reduction of 34% in the preterm birth rate was observed in women treated with Makena, and the children they bore had significantly lower rates of necrotizing enterocolitis, intraventricular hemorrhage, use of supplemental oxygen and mean number of days of respiratory therapy [&lt;ulink linkID="665818" linkType="Reference"&gt;665818&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2014, preclinical data were presented at the 16th ICE/96th ENDO Joint conference in Chicago, IL. In pregnant rhesus monkeys, 17-hydroxyprogesterone-caproate was detectable in serum after initial drug injection and remained detectable for 21 days following the second injection. Difference in steroid levels was not observed, except for lower levels of 17-hydroxyprogesterone caproate in the late-gestation 60 min post initial injection and in mid-gestation on day 27 [&lt;ulink linkID="1570607" linkType="Reference"&gt;1570607&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In September 2009, Hologic signed a development and supply agreement with &lt;ulink linkID="1010293" linkType="Company"&gt;Hospira&lt;/ulink&gt;  to manufacture the product for the companys commercial and clinical use. In February 2015,  AMAG stated that this was still the case [&lt;ulink linkID="1638724" linkType="Reference"&gt;1638724&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2011, &lt;ulink linkID="1060019" linkType="Company"&gt;Baxter Pharmaceutical Solutions&lt;/ulink&gt; had been manufacturing &lt;ulink linkID="1008688" linkType="Company"&gt;&lt;/ulink&gt;the drug  [&lt;ulink linkID="1165824" linkType="Reference"&gt;1165824&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="13726">AMAG Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2014-11-12T00:00:00.000Z</StatusDate><Source id="1611596" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13726">AMAG Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2015-02-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13726">AMAG Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2015-02-17T00:00:00.000Z</StatusDate><Source id="1611596" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1008688">Hologic Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-02-03T00:00:00.000Z</StatusDate><Source id="1167961" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1008688">Hologic Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-02-03T00:00:00.000Z</StatusDate><Source id="1167961" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1008688">Hologic Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-02-03T00:00:00.000Z</StatusDate><Source id="1167961" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17712">Lumara Health Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-03-14T00:00:00.000Z</StatusDate><Source id="1174252" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13722">Adeza Biomedical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-05-08T00:00:00.000Z</StatusDate><Source id="665818" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1008688">Hologic Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-05-03T00:00:00.000Z</StatusDate><Source id="1095599" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1008688">Hologic Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-05-03T00:00:00.000Z</StatusDate><Source id="1095599" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1008688">Hologic Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-10-31T00:00:00.000Z</StatusDate><Source id="1095795" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17712">Lumara Health Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-02-03T00:00:00.000Z</StatusDate><Source id="1167961" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17712">Lumara Health Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-02-03T00:00:00.000Z</StatusDate><Source id="1167961" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13726">AMAG Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2014-11-12T00:00:00.000Z</StatusDate><Source id="1611596" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13726">AMAG Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2014-11-12T00:00:00.000Z</StatusDate><Source id="1611596" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13722">Adeza Biomedical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-05-08T00:00:00.000Z</StatusDate><Source id="665818" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1008688">Hologic Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-05-20T00:00:00.000Z</StatusDate><Source id="869851" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1008688">Hologic Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-02-03T00:00:00.000Z</StatusDate><Source id="1165824" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17712">Lumara Health Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-02-03T00:00:00.000Z</StatusDate><Source id="1167961" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="1008688">Hologic Inc</OwnerCompany><Country id="US">US</Country><Indication id="455">Premature labor</Indication><AwardedIndication>To reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-02-03T00:00:00.000Z</MileStoneDate><Source id="1165824" type="PR"></Source></Row><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="1008688">Hologic Inc</OwnerCompany><Country id="US">US</Country><Indication id="455">Premature labor</Indication><AwardedIndication>To reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-04-20T00:00:00.000Z</MileStoneDate><Source id="665818" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="13722">Adeza Biomedical Corp</OwnerCompany><Country id="US">US</Country><Indication id="455">Premature labor</Indication><AwardedIndication>Prevention of preterm birth in singleton pregnancies</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-01-25T00:00:00.000Z</MileStoneDate><Source id="762198" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01604"><Name>Progesterone receptor</Name><SwissprotNumbers><Swissprot>P06186</Swissprot><Swissprot>P06401</Swissprot><Swissprot>P07812</Swissprot><Swissprot>P79373</Swissprot><Swissprot>Q00175</Swissprot><Swissprot>Q28590</Swissprot><Swissprot>Q63449</Swissprot><Swissprot>Q8AYI2</Swissprot><Swissprot>Q9GLW0</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1008688">Hologic Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1082453">Coldstream Laboratories Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="13726">AMAG Pharmaceuticals Inc</Company><CountAsPrincipalActive>4</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>4</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="14437">Baxter International Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28494">Antares Pharma Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="8">Technology - Delivery/Formulation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C</Smiles></StructureSmiles><Deals><Deal id="111374" title="KV Pharmaceutical to acquire Hologic's Gestiva worldwide     "></Deal><Deal id="133816" title="Baxter Pharmaceutical Solutions to manufacture Hologic's Makena"></Deal><Deal id="159218" title="Antares to develop auto-injection system devices for Lumara's Makena delivery worldwide"></Deal><Deal id="248485" title="Piramal to manufacture Makena (1mL) for premature labor to AMAG Pharma"></Deal><Deal id="248487" title="Pfizer to manufacture and supply AMAG's Makena for premature labor "></Deal></Deals><PatentFamilies><PatentFamily id="1364967" number="WO-2006079064" title="Prefilled needle assisted jet injector"></PatentFamily><PatentFamily id="1504888" number="WO-00009186" title="Needle Assisted Jet Injector"></PatentFamily><PatentFamily id="1659065" number="WO-2004071427" title="Screeninig and treatment methods for prevention of preterm delivery"></PatentFamily><PatentFamily id="2605740" number="WO-2013152323" title="Needle assisted jet injection administration of testosterone compositions"></PatentFamily><PatentFamily id="3855881" number="WO-2017200987" title="Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same"></PatentFamily><PatentFamily id="3886966" number="US-09844558" title="Methods of reducing risk of preterm birth"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hologic Inc" id="1008688"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Evonik Industries AG" id="1036094"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AMAG Pharmaceuticals Inc" id="13726"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="LEO Pharma A/S" id="17774"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Antares Pharma Inc" id="28494"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>